The primary objective of this study is to evaluate the efficacy and safety of fixed dose
combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults
coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects
enrolled will be switched from their current antiretroviral regimen to B/F/TAF will be
followed on treatment for 48 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore